Aethlon Medical (AEMD) Reports Q1 Loss Per Share of $0.18
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/29/2026
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Fed chair Warsh kicks off Jackson Hole keynote address
- PayPal tumbles as Advent, Stripe said to drop $50 bln pursuit
- Oil settles lower on clues about Fed policy, rumors of Hormuz deal
- Dollar jumps after Warsh comments, set for weekly gain
- McKesson reports cybersecurity incident affecting its information systems
- Mizuho is bullish on Broadcom ahead of Sept. 2 earnings, citing 30-quarter streak
- BioNTech ends colorectal cancer mRNA therapy trial early
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Pinterest CFO resigns, interim replacement named
Aethlon Medical Announces Fiscal 2016 First Quarter Results
August 13, 2015 4:05 PM EDTSAN DIEGO, Aug. 13, 2015 /PRNewswire/ --Â Aethlon Medical, Inc. (Nasdaq: AEMD), the pioneer in creating affinity biofiltration devices to treat life-threatening diseases, today announced results for the first quarter of fiscal 2016 ended June 30, 2015.
"In recent months, we executed a series a corporate milestones that improve the future outlook for our organization," stated Jim Joyce, Chairman and CEO of Aethlon Medical. "We continued to strengthen our balance sheet through the completion of a $6 million equity financing and... More
